We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharmaceutical firms’ list prices of common brand drugs are rising much faster than the rate of inflation, concludes an AARP report, which was promptly countered by PhRMA officials, who contend that drug prices are growing at a slower rate than overall healthcare costs.
Federal investigators have expanded their probe into sanofi-aventis’ sales practices, the company said in an April 11 Securities & Exchange Commission (SEC) filing.
A U.S. district court has ruled in favor of a Maine law that would require greater transparency in financial dealings between drugmakers and pharmaceutical benefit managers (PBMs).
A federal district judge has ruled in favor of a widely watched Maine law that would require greater transparency in financial dealings between drugmakers and pharmaceutical benefit managers (PBMs).
The U.S. Attorney’s Office in Boston has expanded its investigation into sanofi-aventis’ sales practices, the company said in an April 11 Securities & Exchange Commission (SEC) filing.
Wholesale prices of common brand drugs are rising much faster than the rate of inflation, concludes an AARP report, which was promptly countered by PhRMA officials, who contend that drug prices are growing at a slower rate than overall healthcare costs.
Biogen Idec and Elan confirmed March 30 that their multiple sclerosis (MS) drug Tysabri has been linked to a third case of a deadly central nervous system disorder — news that analysts believe could close the door on the drug’s potential return to the market.
Pfizer has initiated a plan to trim annual costs by $4 billion within three years in the face of looming generic competition on many of its key products, as well as continuing uncertainty over its arthritis pain drugs.